Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Prisca Yameogo"'
Autor:
Mehreen S Datoo, Hamtandi Magloire Natama, Athanase Somé, Duncan Bellamy, Ousmane Traoré, Toussaint Rouamba, Marc Christian Tahita, N Félix André Ido, Prisca Yameogo, Daniel Valia, Aida Millogo, Florence Ouedraogo, Rachidatou Soma, Seydou Sawadogo, Faizatou Sorgho, Karim Derra, Eli Rouamba, Fernando Ramos-Lopez, Matthew Cairns, Samuel Provstgaard-Morys, Jeremy Aboagye, Alison Lawrie, Rachel Roberts, Innocent Valéa, Hermann Sorgho, Nicola Williams, Gregory Glenn, Louis Fries, Jenny Reimer, Katie J Ewer, Umesh Shaligram, Adrian V S Hill, Halidou Tinto
Publikováno v:
The Lancet. Infectious diseases. 22(12)
Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy over 12 months in the target population of Afric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9960ccb7d631125bcae3e3be558a34f2
https://pubmed.ncbi.nlm.nih.gov/36087586
https://pubmed.ncbi.nlm.nih.gov/36087586
Autor:
Florence Ouedraogo, Reshma Kailath, Amy Flaxman, Andres Noe, Rachidatou Soma, Fernando Ramos Lopez, Katie J. Ewer, Eli Rouamba, Umesh Shaligram, Jenny M. Reimer, Toussaint Rouamba, Federica Cappuccini, Ousmane Traore, Athanase M Some, Prisca Yameogo, Matthew Cairns, M Datoo, Daniel Valia, Benedict O. Orindi, Seydou Sawadogo, Sean C. Elias, Karim Derra, D Bellamy, Faizatou Sorgho, Magloire H Natama, Adrian V. S. Hill, E Mukhopadhyay, Hermann Sorgho, Innocent Valea, Alison M. Lawrie, Moubarak Tegneri, Rachel Roberts, Gregory M. Glenn, Halidou Tinto, Louis Fries, Nicola Williams
Publikováno v:
Lancet, 397 (10287
Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ce074b426a190ef5d943b4c759db00
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/323431
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/323431
Autor:
Karim Derra, Innocent Valea, Reshma Kailath, Katie J. Ewer, Jenny M. Reimer, Fernando Ramos-Lopez, Moubarak Tegneri, Federica Cappuccini, Benedict O. Orindi, Halidou Tinto, Seydou Sawadogo, Rachel Roberts, Toussaint Rouamba, Hermann Sorgho, Daniel Valia, Gregory M. Glenn, Florence Ouedraogo, D Bellamy, Louis Fries, Eli Rouamba, Faizatou Sorgho, Nicola Williams, Athanase M Some, Matthew Cairns, M Datoo, Amy Flaxman, Ousmane Traore, Adrian V. S. Hill, Sean C. Elias, E Mukhopadhyay, Prisca Yameogo, Umesh Shaligram, Alison M. Lawrie, Andres Noe, Rachidatou Soma, Hamtandi Magloire Natama
Publikováno v:
SSRN Electronic Journal.
Background: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 55·8% (97·5% confidence interval [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6526db818d14bd673ec1471f530a2d3a
https://doi.org/10.2139/ssrn.3830681
https://doi.org/10.2139/ssrn.3830681